| Regulatory
Matters |
| |
Bufexamac |
| |
Drospirenone-containing
combined oral contraceptive. |
| |
Irinotecan. |
| |
Naltrexone
for extended-release injectable suspension |
| |
Oral
tacrolimus |
| |
Parenteral
amphotericin B |
| |
Parenteral
amphotericin B |
| |
Promethazine
hydrochloride injection |
| |
Propylthiouracil |
| |
Rivastigmine
transdermal patch |
| |
Saquinavir
mesilate |
| |
Simvastatin
|
| |
Zoledronic
acid |
|
Safety of Medicines |
| |
Antidepressants |
| |
Carbapenems |
| |
Clopidogrel
and proton-pump inhibitors |
| |
Eltrombopag
|
| |
Entacapone/carbidopa/levodopa
|
| |
Gonadotropin-Releasing
Hormone Agonists |
| |
H1N1
pandemic vaccines and antiviral |
| |
Leflunomide |
| |
Natalizumab.
|
| |
SSRIs
and SNRIs |
|
Feature
|
| |
WHO
Prequalification of Medicines Programme |
| |
Workshop
on Pharmacovigilance Systems in West Africa |